Valuation: BioRestorative Therapies, Inc.

Market Cap 10.19M 8.91M 8.18M 7.63M 14.46M 970M 14.7M 98.46M 38.16M 476M 38.27M 37.43M 1.64B P/E 2026 *
-0.81x
P/E 2027 * -0.99x
Enterprise Value 10.19M 8.91M 8.18M 7.63M 14.46M 970M 14.7M 98.46M 38.16M 476M 38.27M 37.43M 1.64B EV / Sales 2026 *
7.25x
EV / Sales 2027 * 4.41x
Free-Float
87.87%
Yield 2026 *
-
Yield 2027 * -
1 day+3.73%
1 week+1.52%
Current month+6.38%
1 month+12.87%
3 months+43.88%
6 months-67.21%
Current year-65.96%
1 week 0.35
Extreme 0.3512
0.41
1 month 0.34
Extreme 0.335
0.43
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
4.43
5 years 0.16
Extreme 0.1593
32
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 55 16/11/2020
Director of Finance/CFO 59 04/11/2021
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 16/11/2020
Director/Board Member 60 29/10/2021
Director/Board Member 28 12/06/2026
Date Insider Type Main position Quantity % Market Cap.
06/10/25Free

Chief Executive Officer

27,344 0.3427%
06/10/25Free

Chief Technology Officer

23,438 0.2938%
14/02/25Other

Chief Executive Officer

791,885 11.4436%
Change 5-day change 1-year change 3-year change Capi.($)
+3.73%+1.52%-74.84%-90.93% 10.19M
-0.82%+4.33%+77.76%+134.23% 58.73B
-3.12%+3.48%+72.79%+94.67% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.68%+45.58%-1.42% 18.8B
-0.89%+9.02%+43.61%-28.44% 17.61B
+2.57%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+19.38%+42.82% - 13.9B
Average +2.45%+8.12%+40.86%+119.52% 24.21B
Weighted average by Cap. +0.99%+7.21%+57.59%+136.19%

Financials

2026 *2027 *
Net sales 1.4M 1.23M 1.13M 1.05M 1.99M 134M 2.03M 13.57M 5.26M 65.61M 5.28M 5.16M 226M 2.31M 2.02M 1.86M 1.73M 3.28M 220M 3.34M 22.34M 8.66M 108M 8.68M 8.49M 372M
Net income -13.52M -11.82M -10.85M -10.12M -19.18M -1.29B -19.51M -131M -50.63M -631M -50.78M -49.67M -2.18B -15.56M -13.6M -12.48M -11.64M -22.07M -1.48B -22.44M -150M -58.25M -727M -58.42M -57.15M -2.5B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
02/07/26 US$0.4000 +3.73% 273,031
01/07/26 US$0.3856 +2.55% 286,084
30/06/26 US$0.3760 +1.62% 635,108
29/06/26 US$0.3700 +0.11% 259,226
26/06/26 US$0.3696 -6.19% 293,900
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.4000USD
Average target price
8.000USD
Spread / Average Target
+1,900.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock